NCT03390296View on ClinicalTrials.gov

OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 27, 2017

Primary Completion Date

February 4, 2022

Study Completion Date

February 4, 2022

Conditions

Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia

Interventions

BIOLOGICAL

Anti-OX40 Agonist Monoclonal Antibody PF-04518600

Given IV

DRUG

Avelumab

Given IV

DRUG

Azacitidine

Given IV or SC

DRUG

Gemtuzumab Ozogamicin

Given IV

DRUG

Glasdegib

Given PO

DRUG

Glasdegib Maleate

Given PO

DRUG

Venetoclax

Given PO

DRUG

Azacitidine

Given IV or SC

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT03390296 - OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter